WO2012173259A1 - ループスアンチコアグラントの検出方法 - Google Patents
ループスアンチコアグラントの検出方法 Download PDFInfo
- Publication number
- WO2012173259A1 WO2012173259A1 PCT/JP2012/065433 JP2012065433W WO2012173259A1 WO 2012173259 A1 WO2012173259 A1 WO 2012173259A1 JP 2012065433 W JP2012065433 W JP 2012065433W WO 2012173259 A1 WO2012173259 A1 WO 2012173259A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- sample
- blood coagulation
- time
- test
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Definitions
- the present invention relates to a method for detecting lupus anticoagulant positivity used for diagnosis of antiphospholipid antibody syndrome.
- LA Lupus anticoagulant
- SLE Systemic Lupus Erythematosus
- APTT activated partial thromboplastin time
- PT prothrombin time
- APS antiphospholipid antibody syndrome
- LA is defined as an immunoglobulin that inhibits phospholipid-dependent clotting reactions in vitro (APTT, kaolin clotting time, diluted Russell snake venom time, etc.) without inhibiting individual clotting factor activities. It is not an antibody.
- anti-cardiolipin- ⁇ 2GPI complex antibody, anti-phosphatidylserine-prothrombin complex antibody, etc. have been found as one type of responsible antibody for LA, and there are measurement systems based on the ELISA method.
- the existence of other LA responsible antibodies other than these is not denied, and even if all of these known responsible antibodies are negative, they may be LA positive.
- a blood clotting time measuring reagent containing phospholipid is generally used as a reagent for detecting LA. If LA is included in the sample, LA binds to the phospholipid in the reagent, so the phospholipid necessary to advance the in vitro clotting reaction is insufficient and the blood clotting time is extended. . Therefore, LA positive can be determined based on the extension of the blood coagulation time.
- the LA detection reagent include APTT, PT, and a reagent for diluted Russell snake venom time (dRVVT).
- Non-Patent Document 2 Blood coagulation correction test using a phospholipid-containing reagent for measuring blood coagulation time, adding normal plasma to the test plasma, and determining the degree to which the blood coagulation time is corrected (normalized) by graphing (Hereinafter, also referred to as “mixing test” or “mixing test”) (Non-Patent Document 2).
- LA detection reagent As a commercially available LA detection reagent, a measurement reagent based on dRVVT called LA test “Gladipore” (manufactured by Medical Biological Research Institute) is used. With this reagent, the presence or absence of LA in the sample is determined based on the ratio of the coagulation time due to the addition of Russell snake venom and the coagulation time due to the addition of raschel snake venom and an excessive concentration of phospholipid.
- Stacrot LA manufactured by Diagnostica Stago
- Stacrot LA manufactured by Diagnostica Stago
- LA positive patients often exhibit thrombotic symptoms, and anticoagulant therapy is often performed when LA is suspected and examination is started.
- anticoagulant therapy is often performed when LA is suspected and examination is started.
- a false positive may occur in APTT and dRVVT, and a false negative may occur in a mixed test.
- heparin As anticoagulant therapy, heparin that is immediately effective and can be administered intravenously in an emergency, and warfarin, an oral anticoagulant, is used for long-term prophylaxis. Warfarin antagonizes the action of vitamin K, thereby suppressing biosynthesis in the liver of factor II (prothrombin), factor VII, factor IX, and factor X among blood coagulation factors. Therefore, in the case of a warfarin user, since the activity of these coagulation factors is reduced, APTT, PT, and dRVVT are greatly extended regardless of the presence or absence of LA. Moreover, in a mixed test, a factor deficient type may be determined regardless of the presence or absence of LA. In addition, heparin activates antithrombin and activates anticoagulant action to suppress coagulation, thus greatly extending the coagulation time regardless of the presence or absence of LA.
- the International Society of Thrombosis and Hemostasis measures LA samples after mixing an equal volume of healthy subject plasma with test plasma to compensate for the lack of coagulation factors in samples from patients treated with warfarin. It is recommended to do.
- the plasma of healthy subjects double-centrifugation is performed so that the platelet count is less than 10 7 / mL, and all blood coagulation factor activities are approximately 100%, and are prepared in-house at each facility and used.
- Non-patent Document 3 Non-patent Document 3
- some blood coagulation factors are very unstable and easily inactivated, and it is very difficult to prepare such normal human plasma, and it is difficult to obtain a stable product. It was.
- the method using normal plasma not only dilutes LA in the test plasma, but also adds substances that interfere with LA measurement in the normal plasma (phospholipids, platelet-derived disrupted membranes, etc.) In some cases, especially when LA is weakly positive, there is a possibility of false negatives.
- the present inventor prepared a blood sample and a diluted sample thereof, and each sample contains a blood coagulation factor before or during measurement of the blood coagulation time of each sample.
- a buffer composition hereinafter sometimes referred to as an auxiliary reagent
- measuring the blood coagulation time for each sample and comparing the blood coagulation time for each sample, the effect of anticoagulation therapy can be reduced.
- the present invention was completed by finding that LA can be detected with better sensitivity and specificity than existing methods.
- this invention provides the detection method of lupus anticoagulant characterized by including the following process (A), (B) and (C).
- A a step of adding a buffer composition containing a blood coagulation factor to a blood sample and a diluted sample of the sample before or during measurement of the blood coagulation time,
- B measuring blood clotting time for each sample in step (A)
- C A step of comparing the blood coagulation time for each sample obtained in step (B)
- the LA detection method of the present invention is characterized by performing the steps (A), (B) and (C). More specifically, as a measurement sample, a blood sample and a diluted sample of the blood sample (hereinafter also simply referred to as a diluted sample) are used, and a buffer composition containing a blood coagulation factor is added to each to increase the blood coagulation time. It is characterized by measuring and comparing its clotting time. In the case of LA-negative patients, the clotting factor is decreased in the diluted sample, resulting in a longer clotting time than in the undiluted sample. In the case of LA positive patients, the clotting factor decreases in the diluted sample, while LA also decreases.
- a measurement sample a blood sample and a diluted sample of the blood sample (hereinafter also simply referred to as a diluted sample) are used, and a buffer composition containing a blood coagulation factor is added to each to increase the blood coagulation time. It is characterized by measuring and comparing its clotting
- the amount of phospholipid not bound to LA in the reagent increases, and the clotting time compared to the undiluted sample.
- the reaction of extending and shortening occurs simultaneously.
- the coagulation time is shorter than that of the undiluted one.
- the blood sample used in the method of the present invention is preferably whole blood or plasma, and is usually prepared by adding an anticoagulant such as sodium citrate to blood collected from a subject.
- an anticoagulant such as sodium citrate
- the present invention is particularly useful when the subject is a blood sample derived from a subject for which LA detection has been difficult.
- blood samples include blood samples such as those taking warfarin, those receiving anticoagulant therapy such as heparin therapy, Vitanmin K deficient, and liver failure patients.
- the dilution factor of the diluted sample is preferably 1.1 times or more, more preferably 1.1 to 3 times, and further preferably 1.5 to 3 times.
- the diluent used for diluting the blood sample is preferably a buffer solution.
- the diluted sample is further diluted and used.
- step (A) of the method of the present invention a buffer composition containing a blood coagulation factor is added to both the blood sample and the diluted sample.
- a buffer composition containing a blood coagulation factor is added to both the blood sample and the diluted sample.
- a buffer composition containing a blood coagulation factor is added to both a blood sample and a diluted sample in order to suppress the coagulation time extension due to a decrease in the coagulation factor activity and increase the sensitivity to LA. To do.
- a blood coagulation factor contained in the buffer composition used in the present invention a blood coagulation factor considered to be deficient in a test blood sample or a coagulation involved in a measurement reaction of a blood coagulation time measurement reagent to be used.
- Factors are appropriately selected and used. Specifically, it contains at least one blood coagulation factor selected from FII, FV, FVII, FVIII, FIX, FX, FXI and FXII, and from FII, FVII, FVIII, FIX, FX, FXI and FXII.
- FII, FVII, FIX and FX are preferable to include one or two or more selected, and it is preferable to include at least one or two or more selected from FII, FVII, FIX and FX.
- FII, FVII and FX when measuring PT, it is preferable to include one or more selected from FII, FVII and FX.
- APTT it is preferable to include one or more selected from FII, FVIII, FIX, FX, FXI and FXII, particularly including one or more selected from FII and FIX. Is preferred.
- dRVVT it is preferable to include the 1 type (s) or 2 or more types chosen from FII and FX.
- the concentration of the coagulation factor is preferably 0.01 to 2.0 U / mL, more preferably 0.1 to 1.0 U / mL after adding the buffer solution composition to the test blood sample.
- the concentration of the coagulation factor in the buffer composition is preferably 0.1 to 20 U / mL, more preferably 1 to 10 U / mL. mL.
- the pH of the buffer solution may be any pH that does not deactivate the blood coagulation factor contained in the auxiliary reagent, and is preferably pH 6-9, more preferably pH 6.5-8.0.
- a known buffer solution such as Good buffer solution such as HEPES can be appropriately used.
- the concentration of the buffer solution is preferably 5 to 100 mM, more preferably 5 to 50 mM, as long as the buffer capacity during storage is maintained.
- glycylglycine or glycylglycylglycine disclosed in JP-B-06-050999 may be added.
- the buffer composition containing the blood coagulation factor is added to the blood sample and the diluted sample before or during measurement of the blood coagulation time.
- adding the buffer composition before measuring the blood coagulation time corresponds to pretreatment of the blood sample and the diluted sample. That is, the buffer composition is added to the blood sample and the diluted sample to pretreat the blood sample or diluted sample, and then the blood clotting time is measured using a blood coagulation measurement reagent.
- adding at the time of measuring the blood coagulation time corresponds to measuring the blood coagulation time by adding the buffer composition to a part of the reagent for blood coagulation measurement. Of these addition times, it is easier to ensure the storage stability of the coagulation factor contained in the buffer composition when the buffer composition is added to the blood sample and the diluted sample before measuring the blood coagulation time. Is preferable.
- the reagent for blood coagulation time measurement may be any phospholipid-dependent blood coagulation time measurement reagent or measurement method that is sensitive to LA.
- Prothrombin time PT
- activated partial thromboplastin time APTT
- Known reagents for measuring diluted PT dPT
- dAPTT diluted APTT
- KCT kaolin clotting time
- dRVVT diluted Russell snake venom time
- These known reagents are appropriately combined with phospholipids such as cephalin, contact factor activators mainly composed of negatively charged substances such as kaolin, compounds that produce Ca 2+ such as calcium chloride, snake venom and the like according to the measurement principle. It will be.
- a dry state or a solution state that is dissolved at the time of use can be appropriately selected.
- Commercially available products can be used as the reagents.
- the PT measurement reagent include Coagpia (registered trademark) PT-N (manufactured by Sekisui Medical), Thrombocheck PT plus (manufactured by Sysmex Corporation), and STA reagent series PT (manufactured by Roche Diagnostics). It is commercially available.
- APTT measurement reagent examples include Coagpia (registered trademark) APTT-N (manufactured by Sekisui Medical), Thrombocheck APTT-SLA (manufactured by Sysmex), APTT liquid “RD” and PTT-LA reagent “RD” (Roche Diagnostic Products) and the like are commercially available.
- APTT-N manufactured by Sekisui Medical
- Thrombocheck APTT-SLA manufactured by Sysmex
- RD APTT liquid
- PTT-LA reagent “RD” Roche Diagnostic Products
- a reagent for dRVVT measurement LA test “Gladipore” (manufactured by Medical Biology Laboratory) is commercially available.
- a reagent kit for LA detection can be prepared by combining one or more of these reagents and a buffer composition (auxiliary reagent) containing the blood coagulation factor of the present invention.
- an average value and a standard deviation (SD) are obtained from measured values of plasma of 20 or more healthy individuals, and an average value + 2SD (in some cases, an average value ⁇ 2SD) is calculated.
- SD standard deviation
- ⁇ Measurement item> (1) APTT Screening Test Using PTT LA reagent “RD” (manufactured by Diagnostica Stago), measurement was performed with an automatic blood coagulation analyzer STA-R (manufactured by Roche Diagnostics). As a cut-off value for determination, a value of measured values of 20 or more healthy subjects + 2SD was used.
- APTT test (method of the present invention) Coagpia APTT-N (manufactured by Sekisui Medical Co., Ltd.) and a buffer solution (hereinafter referred to as auxiliary reagent) containing blood coagulation factors described below, and blood coagulation automatic analyzer CP2000 (manufactured by Sekisui Medical Co., Ltd.) with the measurement parameters shown in Table 1 Measurement was carried out at. Specifically, first, APTT is measured using a sample obtained by adding 5 ⁇ L of an auxiliary reagent to 45 ⁇ L of test plasma (condition 1).
- APTT is measured using a sample obtained by diluting the test plasma with HBS (50 mM HEPES pH 7.5, 150 mM sodium chloride) (plasma 25 ⁇ L: HBS 20 ⁇ L) and adding 5 ⁇ L of an auxiliary reagent (condition 2).
- HBS 50 mM HEPES pH 7.5, 150 mM sodium chloride
- condition 2 APTT of condition 1
- B / A Ratio
- auxiliary reagent 1 Based on HBS (50 mM HEPES pH 7.5, 150 mM sodium chloride), blood coagulation factors shown in Table 2 were added to prepare auxiliary reagent 1 and auxiliary reagent 2. All blood clotting factors are available from Haematologic Technologies Inc. Made using. In Tables 3 to 6 to be described later, the results when the auxiliary reagent 1 was used were shown as “present invention 1”, and the results when the auxiliary reagent 2 was used were shown as “present invention 2”.
- Human Factor II 200 ⁇ g / mL corresponds to 2 U / mL.
- Test plasmas A, B, and C are plasmas collected from patients receiving warfarin. The presence of LA is denied from clinical symptoms.
- Test plasma 1-2 is plasma deficient in blood coagulation factor VIII and blood coagulation factor IX. Not taking anticoagulants.
- Test plasma 3-10 is plasma collected from a patient receiving heparin, an anticoagulant. The presence of LA is denied from clinical symptoms.
- Test plasma 11-37 is plasma collected from patients suspected of having antiphospholipid antibodies due to underlying diseases or clinical symptoms. Of these, 11-24 is plasma collected from patients receiving warfarin.
- the coagulation factor deficient (FVIII and FIX) patient plasma in which LA is negated all of the APTT screening tests exceeded the cut-off value, and it is difficult to differentiate from LA positive.
- the dRVVT test, the mixing test, and the present inventions 1 and 2 were all negative.
- the method of the present invention is a system for supplementing the test plasma with a coagulation factor, it includes a step of comparing before and after dilution, so that the coagulation factor is simply deficient and the inhibitor is positive. The result is not ambiguous. As with the dRVVT test and the mixing test, distinction can be made clearly.
- Table 6 shows the results of the sample group suspected of LA.
- 13 out of 14 cases in the APTT screening test exceeded the cut-off value, but considering the results in Table 3, it is difficult to differentiate from LA positive.
- 13 out of 14 cases in the dRVVT test 13 out of 14 cases were positive, but the results shown in Table 3 suggest that there is a possibility of producing false positives by administration of warfarin, and it is difficult to differentiate between false positives by warfarin and LA positives.
- the negative sample (sample 16) in the APTT screening test does not match the negative sample (sample 19) in the dRVVT test.
- 3 out of 14 cases were positive, and all 3 positive cases were also positive in the present inventions 1 and 2.
- a ⁇ 2GPI Anti- ⁇ 2GPI antibody
- a ⁇ 2GPI anti-phosphatidylserine / prothrombin complex
- aPS / PT anti-phosphatidylserine / prothrombin complex
Abstract
Description
(A)血液凝固時間の測定前又は測定時に、血液試料及び該試料の希釈試料にそれぞれ血液凝固因子を含む緩衝液組成物を添加する工程、
(B)工程(A)の各試料について血液凝固時間を測定する工程、
(C)工程(B)で得られた各試料についての血液凝固時間を対比する工程
尚、補助試薬には、血液凝固因子の安定化剤として公知のものを、適宜添加してもよい。例えば、特公平06-050999号公報で開示されているグリシルグリシンやグリシルグリシルグリシンなどを添加してもよい。
比=(希釈試料の凝固時間)/(血液試料の凝固時間)
この場合、比が大きいほど希釈試料の凝固時間が延長しているのでLA陰性であり、比が小さいほどLA陽性と判断する。
(1)APTTスクリーニング試験
PTT LA試薬「RD」(ディアグノスティカ スタゴ社製)を使用し、血液凝固自動分析装置STA-R(ロシュ・ダイアグノスティックス社製)にて測定を実施した。判定のためのカットオフ値には20名以上の健常者測定値+2SDの値を使用した。
LAテスト「グラディポア」(医学生物学研究所社製)を使用し、血液凝固自動分析装置STA-Rにて測定を実施した。判定のためのカットオフ値には20名以上の健常者測定値+2SDの値を使用した。
PTT LA試薬「RD」(ディアグノスティカ スタゴ社製)を使用し、血液凝固自動分析装置CP2000(積水メディカル社製)にて測定を実施した。正常血漿としてPooled Normal Plasma(以下PNP、Precision Biologic Inc.)を使用した。サンプル混合割合は0、10、20、50、100%に設定し、CP2000のミキシングテスト機能を使用して自動希釈にて測定を行った。判定はグラフを描画し上に凸であればLA陽性とした。
コアグピアAPTT-N(積水メディカル社製)及び後述の血液凝固因子を含む緩衝液(以下、補助試薬)を使用し、表1に示した測定パラメーターで血液凝固自動分析装置CP2000(積水メディカル社製)にて測定を実施した。具体的には、まず被検血漿45μLに補助試薬を5μL添加したものをサンプルとしてAPTTを測定する(条件1)。次に被検血漿をHBS(50mM HEPES pH7.5、150mM塩化ナトリウム)にて希釈したもの(血漿25μL:HBS20μL)に補助試薬を5μL添加したものをサンプルとしてAPTTを測定する(条件2)。条件1のAPTTをA秒、条件2のAPTTをB秒とするとき、B/A(Ratio)を判定のための測定値として算出する。後述の本発明1,2では希釈時の凝固時間短縮によってLAの有無を判別するため、Ratioが小さい方が陽性となる。判定のためのカットオフ値には20名以上の健常者血漿の測定値-2SDの値を使用した。
HBS(50mM HEPES pH7.5、150mM塩化ナトリウム)をベースに、表2に示した血液凝固因子を添加して補助試薬1及び補助試薬2を調製した。血液凝固因子は全てHaematologic Technologies Inc.製を使用した。
尚、後述の表3から表6において、補助試薬1を用いた場合の結果を「本発明1」、補助試薬2を用いた場合の結果を「本発明2」として表した。
・被検血漿A,B,Cはワルファリンの投与を受けている患者より採取した血漿である。臨床症状等より、LAの存在は否定されている。
・被検血漿1-2は、血液凝固第VIII因子及び血液凝固第IX因子が欠乏した血漿である。抗凝固剤の投与を受けていない。
・被検血漿3-10は、抗凝固剤であるヘパリンの投与を受けている患者より採取した血漿である。臨床症状等より、LAの存在は否定されている。
・被検血漿11-37は、基礎疾患や臨床症状から抗リン脂質抗体の存在が疑われる患者より採取した血漿である。これらのうち、11-24はワルファリン投与を受けている患者より採取した血漿である。
表3に示すとおり、ワルファリン投与・非LA群では、APTTスクリーニング試験において全てカットオフ値以上となり、LA陽性との鑑別は困難である。また、dRVVT試験については3例中2例が偽陽性となった(表中「陽性*」で示した)。一方、混合試験及び本発明1,2では全て陰性となった。
ワルファリン非投与群では、13例中6例が全ての項目で陽性となり、2例が陰性となったためこの8例については陽性・陰性の鑑別可能であった。残り5例中、本発明1,2のみが陽性となった検体30について、aβ2GPIとaPS/PTを測定したところ、aβ2GPIが陽性であったため、dRVVT及び混合試験の偽陰性で、実際にはLA陽性である可能性が非常に高いと考えられる。
Claims (5)
- 次の工程(A)、(B)及び(C)を含むことを特徴とするループスアンチコアグラントの検出方法。
(A)血液凝固時間の測定前又は測定時に、血液試料及び該試料の希釈試料にそれぞれ血液凝固因子を含む緩衝液組成物を添加する工程、
(B)工程(A)の各試料について血液凝固時間を測定する工程、
(C)工程(B)で得られた各試料についての血液凝固時間を対比する工程 - 血液凝固因子が、FII、FV、FVII、FVIII、FIX、FX、FXI及びFXIIから選ばれる1種又は2種以上である請求項1記載の検出方法。
- 血液試料が、全血又は血漿である請求項1又は2記載の検出方法。
- 血液凝固時間の測定前に、血液試料に、血液凝固因子を含む緩衝液組成物を添加する請求項1~3のいずれか1項記載の検出方法。
- 血液凝固時間の測定手段が、活性化トロンボプラスチン時間又は希釈ラッセル蛇毒時間である請求項1~4のいずれか1項記載の検出方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280029871.5A CN103649758B (zh) | 2011-06-17 | 2012-06-15 | 狼疮抗凝物的检测方法 |
KR1020137033381A KR101979865B1 (ko) | 2011-06-17 | 2012-06-15 | 루프스 안티코아귤란트의 검출방법 |
ES12800902.4T ES2652495T3 (es) | 2011-06-17 | 2012-06-15 | Método para detectar anticoagulantes lúpicos |
EP12800902.4A EP2722674B1 (en) | 2011-06-17 | 2012-06-15 | Method for detecting lupus anticoagulants |
JP2013520612A JP6028314B2 (ja) | 2011-06-17 | 2012-06-15 | ループスアンチコアグラントの検出方法 |
CA2839117A CA2839117C (en) | 2011-06-17 | 2012-06-15 | Method for detecting lupus anticoagulants |
US14/127,026 US9977038B2 (en) | 2011-06-17 | 2012-06-15 | Method for detecting lupus anticoagulants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011135173 | 2011-06-17 | ||
JP2011-135173 | 2011-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012173259A1 true WO2012173259A1 (ja) | 2012-12-20 |
Family
ID=47357237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/065433 WO2012173259A1 (ja) | 2011-06-17 | 2012-06-15 | ループスアンチコアグラントの検出方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9977038B2 (ja) |
EP (1) | EP2722674B1 (ja) |
JP (1) | JP6028314B2 (ja) |
KR (1) | KR101979865B1 (ja) |
CA (1) | CA2839117C (ja) |
ES (1) | ES2652495T3 (ja) |
WO (1) | WO2012173259A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE540132C2 (sv) | 2014-05-22 | 2018-04-10 | Zafena Ab | Analysmetod för bestämning av antikoagulanter i blod eller blodplasma |
JP6499488B2 (ja) * | 2015-03-31 | 2019-04-10 | 学校法人東日本学園 | 凝固時間の測定方法、ループスアンチコアグラントの存否の判定方法及びループスアンチコアグラント検出用試薬キット |
JP6837851B2 (ja) * | 2017-01-31 | 2021-03-03 | シスメックス株式会社 | 血液検体の判定方法、並びに血液検体の分析のための装置及びコンピュータプログラム |
JP6873833B2 (ja) * | 2017-06-09 | 2021-05-19 | シスメックス株式会社 | 血液検体の判定方法、血液検体分析装置及びコンピュータプログラム |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0650999B2 (ja) | 1988-09-12 | 1994-07-06 | 日本商事株式会社 | 血液凝固因子安定化法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543145A (en) * | 1984-09-17 | 1996-08-06 | Baxter International, Inc. | Pharmaceutical composition and method for the suppression of factor VIII inhibitor production |
US4877741A (en) | 1988-10-24 | 1989-10-31 | The United States Of America As Represented By The Secretary Of The Air Force | Treatment of human plasma with brown recluse spider toxin to emulate a lupus anticoagulant |
DE602005006633D1 (de) * | 2004-02-06 | 2008-06-26 | Sysmex Corp | Reagenziensatz zum Nachweis von Lupus-Antikoagulant. |
US7932021B2 (en) | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
CN101221189B (zh) | 2007-01-12 | 2012-08-15 | 上海太阳生物技术有限公司 | 一种用于测定活化部分凝血活酶时间aptt的体外诊断试剂盒 |
PT2290370E (pt) | 2008-06-18 | 2015-02-27 | Sekisui Medical Co Ltd | Método de determinação da causa do prolongamento do tempo de coagulação do sangue |
-
2012
- 2012-06-15 CA CA2839117A patent/CA2839117C/en active Active
- 2012-06-15 JP JP2013520612A patent/JP6028314B2/ja active Active
- 2012-06-15 EP EP12800902.4A patent/EP2722674B1/en active Active
- 2012-06-15 ES ES12800902.4T patent/ES2652495T3/es active Active
- 2012-06-15 US US14/127,026 patent/US9977038B2/en active Active
- 2012-06-15 WO PCT/JP2012/065433 patent/WO2012173259A1/ja active Application Filing
- 2012-06-15 KR KR1020137033381A patent/KR101979865B1/ko active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0650999B2 (ja) | 1988-09-12 | 1994-07-06 | 日本商事株式会社 | 血液凝固因子安定化法 |
Non-Patent Citations (6)
Title |
---|
"Update of the guidelines for lupus anticoagulant detection", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 7, 2009, pages 1737 - 1740 |
INTERNATIONAL CONSENSUS STATEMENT ON PRELIMINARY CLASSIFICATION CRITERIA FOR DEFINITE ANTIPHOSPHOLIPID SYNDROME, ARTHRITIS & RHEUMATISM, vol. 42, no. 7, July 1999 (1999-07-01), pages 1309 - 1311 |
KAZUHIKO KAGAWA: "Blood coagulation compensation test", MODERN MEDICAL LABORATORY, vol. 34, no. 8, 1 August 2006 (2006-08-01), pages 735 - 742, XP008172319 * |
KENSA TO GIJUTSU, vol. 34, no. 8, August 2006 (2006-08-01), pages 735 - 742 |
MASAHIRO IEKO ET AL.: "Cross-Mixing Test to Detect Lupus Anticoagulant for Diagnosis of Antiphospholipid Syndrome", THE JAPANESE JOURNAL OF CLINICAL PATHOLOGY, vol. 57, no. 10, 25 October 2009 (2009-10-25), pages 990 - 998, XP008172335 * |
NOBUKO KANNO ET AL.: "Lupus Anticoagulant Sokutei no Tameno Kessho Kentai Sakusei to Kensa no Genjo", MODERN MEDICAL LABORATORY, vol. 37, no. 13, 1 December 2009 (2009-12-01), pages 1484 - 1490, XP008172316 * |
Also Published As
Publication number | Publication date |
---|---|
CA2839117C (en) | 2019-09-17 |
KR101979865B1 (ko) | 2019-05-17 |
EP2722674B1 (en) | 2017-11-29 |
KR20140034230A (ko) | 2014-03-19 |
ES2652495T3 (es) | 2018-02-02 |
JPWO2012173259A1 (ja) | 2015-02-23 |
CN103649758A (zh) | 2014-03-19 |
JP6028314B2 (ja) | 2016-11-16 |
US20140127725A1 (en) | 2014-05-08 |
EP2722674A4 (en) | 2015-02-25 |
US9977038B2 (en) | 2018-05-22 |
EP2722674A1 (en) | 2014-04-23 |
CA2839117A1 (en) | 2012-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Patzke et al. | Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin | |
JP5537338B2 (ja) | ループスアンチコアグラント検出用試薬キット及びループスアンチコアグラントの存否を判定する方法 | |
JP6025105B2 (ja) | ループスアンチコアグラント検出用血液凝固時間の測定方法 | |
WO2009153964A1 (ja) | 血液凝固時間の延長原因の判定法 | |
JP5903215B2 (ja) | ループスアンチコアグラント検出用試薬キット及びループスアンチコアグラントの存否を判定する方法 | |
JP6028314B2 (ja) | ループスアンチコアグラントの検出方法 | |
van den Besselaar et al. | A comparative study of conventional versus new, magnesium-poor Vacutainer® Sodium Citrate blood collection tubes for determination of prothrombin time and INR | |
JP6864008B2 (ja) | 抗リン脂質抗体症候群に関連するループス抗凝固因子(la)を特定するための方法およびキット | |
JP5891491B2 (ja) | 試料中の総プロテインsタンパク質量の測定試薬及び測定方法 | |
Suzuki et al. | Fibrinogen levels measured by the dry hematology method are lower than those measured by the Clauss method under a high concentration of heparin | |
JP2005156482A (ja) | 血液凝固能測定方法および血液凝固能測定用試薬 | |
CN103649758B (zh) | 狼疮抗凝物的检测方法 | |
Réger et al. | Detection of high-risk thrombophilia with an automated, global test: the Coagulation Inhibitor Potential assay | |
WO2014163170A1 (ja) | プロテインsの活性測定試薬キット及び活性測定方法 | |
Rossignon et al. | Circulating Inhibitor against Factor X: A Rare Cause of Hemorrhagic Diathesis | |
WO2017033897A1 (ja) | Iii型高脂血症の判定を補助する方法 | |
Panes et al. | EVALUATION OF CLOT LYSIS TIME WITH PLATELETS: CORRELATION WITH CARDIOVASCULAR RISK MARKERS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12800902 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013520612 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2012800902 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2839117 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20137033381 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14127026 Country of ref document: US |